Core Viewpoint - The company XinTiandi has received approval from the National Medical Products Administration for its drug "Vildagliptin Tablets," which is classified as a Category 4 chemical drug and is effective for the treatment of type 2 diabetes [1] Group 1: Drug Approval and Details - The drug Vildagliptin Tablets has been granted a registration certificate with a validity period of 24 months, expiring on July 21, 2030 [1] - The original developer of Vildagliptin is Novartis Pharmaceuticals, and it is marketed in China under the name "Jiaweile" [1] - Vildagliptin works by increasing the levels of incretin hormones, which helps to reduce blood glucose levels by decreasing liver glucose production [1] Group 2: Company Impact - The approval of Vildagliptin Tablets signifies that the product meets the necessary registration requirements, allowing the company to produce and sell the drug in the domestic market [1] - This approval will enhance the company's product portfolio and improve its market competitiveness [1]

Group 1 - The core point of the article is that Xintiandi has received approval from the National Medical Products Administration for its drug, Vildagliptin Tablets [2] Group 2 - The drug Vildagliptin Tablets has been officially registered, indicating a significant milestone for the company in the pharmaceutical industry [2]

新天地（SZ 301277，收盘价：15.58元）7月29日晚间发布公告称，新天地药业股份有限公司于近日收 到国家药品监督管理局核准签发的《药品注册证书》。产品名称为"维格列汀片"。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company Xin Tiandi (301277.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of Vildagliptin tablets, which are used for the treatment of type 2 diabetes [1] Group 1: Product Information - Vildagliptin is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, originally developed by Swiss pharmaceutical company Novartis, and marketed in China under the name "Jiaweile" [1] - The drug works by rapidly inhibiting DPP-4 activity, leading to increased levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhances the sensitivity of beta cells to glucose and promotes glucose-dependent insulin secretion [1] Group 2: Mechanism of Action - Vildagliptin increases the sensitivity of alpha cells to glucose, improving the alignment between glucose levels and glucagon secretion [1] - During hyperglycemia, Vildagliptin elevates the levels of intestinal glucagon-like peptides, increasing the insulin/glucagon ratio, which results in reduced hepatic glucose production and consequently lowers blood sugar levels [1]

公告显示，维格列汀片适用于治疗2型糖尿病，主要成分维格列汀是一种选择性二肽-肽酶-4(DPP-4)抑制 剂，给药后能快速抑制DPP-4活性，使空腹和餐后内源性肠降血糖素GLP-1(胰高血糖素样多肽-1)和 GIP(葡萄糖依赖性促胰岛素多肽)的水平升高，进而增加β细胞对葡萄糖的敏感性,促进葡萄糖依赖性胰 岛素的分泌。通过增加内源性GLP-1水平，维格列汀还能够增加α细胞对葡萄糖的敏感性，使葡萄糖水 平与胰高血糖素的分泌量契合度提高。在高血糖期间，维格列汀通过升高肠降血糖素水平，增加胰岛 素/胰高血糖素的比率，导致空腹和餐后肝脏葡萄糖生成量减少，进而降低血糖。 新天地（301277）(301277.SZ)公告，公司近日收到国家药品监督管理局核准签发的《药品注册证 书》，涉及药品名称为：维格列汀片。 ...

智通财经APP讯，新天地(301277.SZ)公告，公司近日收到国家药品监督管理局核准签发的《药品注册证 书》，涉及药品名称为：维格列汀片。 公告显示，维格列汀片适用于治疗2型糖尿病，主要成分维格列汀是一种选择性二肽-肽酶-4(DPP-4)抑制 剂，给药后能快速抑制DPP-4活性，使空腹和餐后内源性肠降血糖素GLP-1(胰高血糖素样多肽-1)和 GIP(葡萄糖依赖性促胰岛素多肽)的水平升高，进而增加β细胞对葡萄糖的敏感性,促进葡萄糖依赖性胰 岛素的分泌。通过增加内源性GLP-1水平，维格列汀还能够增加α细胞对葡萄糖的敏感性，使葡萄糖水 平与胰高血糖素的分泌量契合度提高。在高血糖期间，维格列汀通过升高肠降血糖素水平，增加胰岛 素/胰高血糖素的比率，导致空腹和餐后肝脏葡萄糖生成量减少，进而降低血糖。 ...

Group 1 - The company, New World (301277), has recently received the drug registration certificate for Vildagliptin tablets from the National Medical Products Administration [1] - Vildagliptin tablets are indicated for the treatment of type 2 diabetes [1]

新天地（301277）公告，近日收到国家药品监督管理局核准签发的《药品注册证书》，药品通用名称为 维格列汀片。维格列汀片适用于治疗2型糖尿病，主要成分维格列汀是一种选择性二肽-肽酶-4(DPP-4)抑 制剂。 ...

Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has shown continuous improvement in profitability, driven by market expansion and innovation in research and development [2][4]. Financial Performance - In the 2024 annual report, the company reported operating revenue of 7.503 billion yuan, a slight decrease year-on-year; net profit reached 410 million yuan, an increase of 14.34%; and non-net profit was 312 million yuan, up 18.97% [2]. - Both net profit and non-net profit have achieved four consecutive years of growth, reaching the highest levels since 2010 [2]. Dividend Distribution - The company plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [3]. Competitive Advantages - Northeast Pharmaceutical is a significant drug production and export base in China, with integrated production bases for raw materials and formulations [4]. - The company has a diverse product line covering ten major series, including vitamins and anti-infection drugs, with products exported to over 100 countries and regions [4]. - The company increased its R&D investment to 149 million yuan, a year-on-year growth of 7.55% [4][5]. Innovation and Product Development - In 2024, the company successfully obtained one innovative drug candidate and approved five generic drugs for production [5]. - The company received approval for raw material drug listings and registered certificates for several new products, enhancing its product portfolio [5]. - The company’s raw materials, such as L-carnitine and vitamin C, received CEP certification from the European Medicines Agency, allowing sales in the EU high-end pharmaceutical market [5]. Export Business - The export business generated revenue of 902 million yuan in 2024, reflecting a year-on-year increase of 26.30%, with a gross margin growth of 5.89% [6]. Strategic Acquisition - The company is expanding into the biopharmaceutical sector by acquiring Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., focusing on cell immunotherapy technology [7][8]. - Dingcheng Peptide Source has developed a complete technical platform for TCR-T and CAR-T cell therapy products targeting various cancers [7]. - This acquisition is expected to enhance the company's competitiveness in the biopharmaceutical field and accelerate the R&D and commercialization of innovative drugs [8].